VCEL News and Press, Vericel Corporation From 10/21/21

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2021 financial results and busin...

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stan...

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Patrick J. Fowler as Senior Vice President, Corporate Development and Strategy, effective...

BDSI trades at extremely low P/E and EV/S ratios for a company that is still growing at a good clip. Management has cleared up a few concerns by finally starting the process of buying back shares and stopping the dilution that happened for so long. The largest risk remains ongoing...

The following slide deck was published by Vericel Corporation in conjunction with their 2021 Q2 earnings call. For further details see: Vericel Corporation 2021 Q2 - Results - Earnings Call Presentation

Image source: The Motley Fool. Vericel (NASDAQ: VCEL) Q2 2021 Earnings Call Aug 04, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Vericel (VCEL) Q2 2021 Earnings Call Transcript

Vericel Corporation (VCEL) Q2 2021 Earnings Conference Call August 4, 2021 08:30 ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investors Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call P...

Vericel (NASDAQ:VCEL): Q2 GAAP EPS of -$0.08 in-line. Revenue of $39.52M (+97.5% Y/Y) beats by $2.74M. Gross margin of 68%, compared to 57% in Q2 2020. Non-GAAP adjusted EBITDA of $7.8M, or 20% of net revenue, compared to adjusted EBITDA loss of $3.5M in Q2 2020. Operating cash flow of $4.8M....

Second Quarter Total Net Revenue Increased 97% to $39.5 Million Full-Year 2021 Revenue Guidance Raised to $168-$171 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader ...

The FDA sent MediWound a Complete Response Letter for their eschar removal treatment, NexoBrid. The FDA was not able to inspect the company’s manufacturing facilities due to pandemic travel restrictions. I believe they will be able to address the cited issues in the CRL, howeve...